Molsidomine in the treatment of patients with angina pectoris

The New England Journal of Medicine
P A MajidJ P Roos

Abstract

Molsidomine, a new long-acting vasodilator, was administered intravenously (0.03 mg per kilogram of body weight) to two groups of six patients with stable anginapectoris. In the first group, studied during exercise-induced angina, the drug shortened the duration of pain and reduced electrocardiographically measured ST-segment depression, mean systemic arterial pressure, and mean pulmonary wedge pressure. Cardiac output and heart rate remained unchanged. In the second group, studied during pacing-induced angina, the drug reduced both left ventricular pressures and angiographically estimated ventricular volumes and improved the ejection fraction. In a double-blind crossover comparison with a placebo, molsidomine (2 mg three times daily) reduced the frequency of anginal attacks and the consumption of nitroglycerin tablets in 14 patients. During exercise testing on a treadmill a statistically significant reduction in ST-segment depression lasted for up to six hours. These studies suggest that molsidomine acts like nitroglycerin but its effects last longer. We conclude that molsidomine is effective in preventing the symptoms of angina pectoris. (N Engl J Med 302:1-6, 1980).

References

Jun 19, 1978·European Journal of Clinical Pharmacology·S GuerchicoffF Díaz
Jun 19, 1978·European Journal of Clinical Pharmacology·K R KarschH Kreuzer
Oct 31, 1970·Lancet·B Sharma, S H Taylor
Nov 1, 1973·Circulation·R E Goldstein, S E Epstein
Sep 1, 1973·Circulation·A P KlausR S Ross
Sep 1, 1968·The American Journal of Cardiology·E H SonnenblickE Braunwald
Mar 1, 1969·Progress in Cardiovascular Diseases·R A Bruce, T R Hornsten
Jun 1, 1970·Japanese Journal of Pharmacology·F TakenakaE Tsutsumi
Mar 1, 1970·Japanese Journal of Pharmacology·K KikuchiA Nagaoka

❮ Previous
Next ❯

Citations

Oct 1, 1993·Clinical Cardiology·G KoberH Klepzig
Aug 1, 1982·Naunyn-Schmiedeberg's Archives of Pharmacology·V B FiedlerJ Scholtholt
Jan 1, 1984·European Journal of Clinical Pharmacology·R BergstrandJ Ostrowski
Jan 1, 1982·European Journal of Clinical Pharmacology·A Vogt, H Kreuzer
Aug 1, 1989·Cardiovascular Drugs and Therapy·T M IbrahimS Degre
Oct 3, 1980·European Journal of Pharmacology·G J Gross, M Gharaibeh
Mar 12, 2004·Anti-cancer Drugs·Andrea Senff-RibeiroMaria B M Oliveira
Sep 1, 1991·British Journal of Clinical Pharmacology·O Spreux-VaroquauxC Advenier
Jan 1, 1991·Fundamental & Clinical Pharmacology·O Spreux-VaroquauxC Advenier
Apr 1, 1993·The Journal of Pharmacy and Pharmacology·Y ZhangC Advenier
Jan 1, 1985·European Journal of Clinical Pharmacology·J P van MantgemA W Matroos
Jan 1, 1987·Issues in Comprehensive Pediatric Nursing·M K Donovan
Feb 9, 2002·Cell Biochemistry and Function·Silvia M S C CadenaMaria Benigna Martinelli de Oliveira
Feb 1, 1982·Circulation·Y KoiwayaM Nakamura
Feb 1, 1990·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J P VinelJ P Pascal
Nov 1, 1984·Clinical Cardiology·T IshikawaK Tanaka
Jun 17, 2004·British Journal of Cancer·A Senff-RibeiroM B M Oliveira
Jan 1, 1984·European Journal of Clinical Pharmacology·A E BalestriniA Vazquez
May 29, 2012·Chemical Communications : Chem Comm·Ana PetronilhoMartin Albrecht
Aug 1, 1986·British Journal of Pharmacology·J P CanoA Serradimigni
May 1, 1982·Basic Research in Cardiology·V B Fiedler, R E Nitz
Jan 1, 1987·Pharmacotherapy·R E Nitz, V B Fiedler
Sep 21, 2010·American Journal of Physiology. Heart and Circulatory Physiology·Lennart G BongartzJaap A Joles
Sep 27, 2003·Melanoma Research·Andrea Senff-RibeiroMaria Benigna Martinelli Oliveira
Apr 11, 2002·Chemical Reviews·Peng George WangAdam J Janczuk
May 9, 2021·International Journal of Health Economics and Management·William EncinosaThomas M Selden

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.